Market growth is largely driven by the harmful effects (lingering role) of
cytotoxic drugs, rising incidence of cancer, an increasing number of oncology
drug approvals, and improving regulatory guidelines regarding the safe handling
of hazardous drugs. However, the high cost of implementation of CSTDs, along
with a lack of reimbursement